Lucid Diagnostics (NASDAQ:LUCD) and Nuvation Bio (NYSE:NUVB) Critical Survey

Nuvation Bio (NYSE:NUVB – Get Free Report) and Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nuvation Bio and Lucid Diagnostics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio 1 2 9 0 2.67
Lucid Diagnostics 1 0 4 0 2.60

Nuvation Bio currently has a consensus price target of $12.89, suggesting a potential upside of 228.38%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 926.35%. Given Lucid Diagnostics’ higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than Nuvation Bio.

Profitability

This table compares Nuvation Bio and Lucid Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuvation Bio -67.38% -45.69% -18.54%
Lucid Diagnostics -892.75% N/A -142.71%

Insider & Institutional Ownership

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Nuvation Bio and Lucid Diagnostics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvation Bio $201.73 million 6.87 -$204.63 million ($0.40) -9.81
Lucid Diagnostics $5.44 million 15.25 -$58.01 million ($0.40) -1.02

Lucid Diagnostics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nuvation Bio has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Summary

Nuvation Bio beats Lucid Diagnostics on 7 of the 13 factors compared between the two stocks.

About Nuvation Bio

(Get Free Report)

Nuvation Bio is a biopharmaceutical company focused on developing and commercializing treatments for cancer. Founded in 2018 by physician and biotechnology executive David Hung, the company is headquartered in New York and is led by Hung as founder and chief executive officer. Its commercial product, Ibtrozi (taletrectinib), is an oral targeted therapy approved in the United States for adults with ROS1-positive non-small cell lung cancer. Nuvation Bio also develops investigational oncology medicines, including therapies targeting specific genetic changes and other features of cancer.

About Lucid Diagnostics

(Get Free Report)

Lucid Diagnostics is a U.S.-based medical diagnostics company focused on identifying esophageal precancer and cancer. Its primary offering is EsoGuard, a DNA-based test designed to detect cellular changes associated with Barrett’s esophagus, a condition that can increase the risk of esophageal cancer. The test is designed to work with EsoCheck, a swallowable balloon device that collects cells from the esophagus for analysis. Together, the products are intended to provide a less invasive approach to evaluating patients for esophageal disease than traditional endoscopic procedures.

Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.